Global Protein Labeling Market Size, Share & Industry Trends Analysis Report By Method, By Product, By Application, By Regional Outlook and Forecast, 2022 – 2028

Global Protein Labeling Market Size, Share & Industry Trends Analysis Report By Method, By Product, By Application, By Regional Outlook and Forecast, 2022 – 2028

  • June 2022 •
  • 307 pages •
  • Report ID: 6309649 •
  • Format: PDF
The Global Protein Labeling Market size is expected to reach $3.2 billion by 2028, rising at a market growth of 7.5% CAGR during the forecast period.

Proteins are the biggest macro molecules in a living creature, as they are essential for its survival. In addition, proteins engage with other bio molecules and carry out duties to keep the cell alive once they are created within a cell. As a result, proteomics and protein chemistry is being used to investigate the protein binding mechanism. The majority of these techniques revolve around the ability to create genetic fusions that selectively target proteins, resulting in unique features for selective protein imaging, manipulation, and trapping within complex biochemical settings. To conduct successful protein labeling, a variety of procedures are used.

There is an employment of a variety of methods to label proteins, including the use of specific enzymes or probes. Alkaline phosphatase (AP) and horseradish peroxidase are two often utilized enzyme-protein conjugates (HRP). Enzyme-protein labeling systems have a number of advantages, including signal amplification, a variety of signal outputs, and a wide range of substrates for each enzyme. Fluorescent, chemiluminescent, and colorimetric detection are common signal outputs. These signal outputs are suited for immunohistochemistry (IHC) or immunofluorescent (IF)-based detection applications in cells and tissues because of the wide range of signal outputs.

For examining the function and distribution of proteins in living and fixed cells, the SNAP-tag, CLIP-tag, and ACP-tag/MCP-tag protein labeling technologies provide a new alternative to standard fluorescent proteins. Covalent protein labeling makes imaging mammalian proteins in living cells easier and more versatile, as well as allowing for protein capture in vitro. A fusion protein is created by covalently attaching a single genetic construct to a range of substrates, such as fluorophores, biotin, and beads, to provide a potent tool for investigating proteins.

COVID-19 Impact

COVID-19 has quickly expanded in terms of confirmed cases and reported deaths, many countries are among the worst impacted by this pandemic. Owing to lockdowns, travel bans, and business shutdowns, the COVID-19 has had a negative impact on economies and businesses in a number of countries. The closure of various plants and factories has had a severe influence on comprehensive supply chains, negatively affecting manufacturing, delivery schedules, and product sales in the market. A few companies have already stated that there may be delays in product deliveries and a drop in future sales. Moreover, travel prohibitions implemented by countries are harming prospects for commercial cooperation and partnerships.

Market Growth Factors

Increasing healthcare expenditure to create more health prospects

Healthcare spending can lead to greater health opportunities, which can help to enhance human capital and increase productivity, boosting economic performance. As a result, assessing the phenomena of healthcare spending in a country is critical. Overall, the findings point to a robust link between healthcare spending and economic variables such as income, GDP, and labor productivity. Healthcare spending is positively related to labor productivity, personal spending, and GDP indicators. With more spending by regional governments and healthcare bodies on the enhancement of medical technologies like protein labeling, the method of attaching fluorescent dyes to functional groups in biomolecules such that fluorescence imaging can easily be used to see them.

Rising R&D spending on healthcare industry

The ability of health research to contribute to the formation of advanced medical technology like protein labeling accounts for its significant effect. The medical association of various now spends significantly more on research and development (R&D) than other countries, which has been proved to contribute to innovation and the eventual development of a knowledge-based economy. Improving R&D investment is one of those investments that reap a huge reward for the comprehensive industry as it innovates and establishes a knowledge-based economy.

Market Restraining Factors

Shortage of skilled and competent professionals

In some region, there is a huge scarcity of skilled professionals, which is hindering the recovery & progress. Along with that, there is a severe issue of unemployment and a lack of chances stymie social cohesion and enhancement. Unemployed or underemployed people may have abilities that are in short supply everywhere. Companies have identified the top three effects of skills shortages as being compelled to hire ill-suited personnel, lost production opportunities, and decreased company investment and product development—all of which hamper companies’ ability to compete. Productivity might suffer as a result of a shortage of qualified workers, resulting in longer production times, higher operating costs, and other concerns.

Method Outlook

Based on Method, the market is segmented into In-vitro (Enzymatic, Dye-based, Co-translational, Site-specific, Nanoparticle, and Others) and In-vivo (Photoreactive, Radioactive, and Others). The in-vitro segment procured the highest revenue share in the protein labeling market in 2021. The in-vitro labeling method is used to identify the usage of a drug or alcohol from a sample taken from a human body that is not in a live organism, such as a test tube. In vitro, diagnostic medical equipment is tests that are performed on biological samples in order to ascertain a person’s health state.

Product Outlook

Based on Product, the market is segmented into Reagents, Kits, and Services. The Kit segment acquired a substantial revenue share in the protein labeling market in 2021. The Protein Labeling Kit contains everything required to label an antibody or protein with amine-reactive green-fluorescent Alexa Fluor 488 dye (ex/em 495/519 nm). The kit is designed to label 1 mg of IgG antibody with Alexa Fluor 488 in a single reaction. Other proteins with a molecular weight greater than 20 kDa can also be tagged in modest doses.

Application Outlook

Based on Application, the market is segmented into Immunological Techniques, Cell-based Assays, Fluorescence Microscopy, Protein Microarray, and Mass Spectrometry. The immunological techniques witnessed the maximum revenue share in the protein labeling market in 2021. Flow cytometry, immunoassays, western blotting, and immunofluorescence are all examples of immunological methods that use labels. These methods are mostly employed in cancer R&D, autoimmune disease R&D, and pharmaceutical R&D. It is commonly used to identify diabetes, systemic lupus erythematosus, rheumatoid arthritis, lung disorders, neurological disease, and gastrointestinal disease.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the protein labeling market with the largest revenue share in 2021. The number of immunological techniques, fluorescence microscopy, western blotting, ELISA, and cell-based assays has expanded dramatically in this region. The widespread use of protein tagging techniques in disease diagnosis-related investigations will help the region generate even more cash.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Merck Group, PerkinElmer, Inc., General Electric (GE) Co., F. Hoffmann-La Roche Ltd., Kaneka Corporation, New England BioLabs Inc., Promega Corporation, LI-COR, Inc., and SeraCare Life Sciences.

Strategies deployed in Protein Labeling Market

Apr-2022: PerkinElmer unveiled two ready-to-use HTRF and AlphaLISA no-wash assay kits. These products would swiftly and simply detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.

Mar-2022: Promega joined hands with FUJIFILM Cellular Dynamics, a leading global developer, and manufacturer of human-induced pluripotent stem cell (iPSC) technologies. This collaboration would combine bioluminescent reporter technology used to study cellular signaling and transcriptional activity in iPSCs, allowing researchers to develop novel assays to observe cellular biology in a system that better reflects how cells behave in the human body.

Jan-2022: Thermo Fisher Scientific took over PeproTech, a leading developer and manufacturer of recombinant proteins. This acquisition would enable both companies to better serve the pharma and biotech customers by including new capabilities in the current offering.

Sep-2021: PerkinElmer took over BioLegend, a leading worldwide provider of life science antibodies and reagents. This acquisition aimed to expand the company’s life science franchise into high-growth areas like cytometry, multiplex assays, proteogenomics, recombinant proteins, magnetic cell separation, and bioprocessing.

Nov-2019: Promega teamed up with Merck, a technology company. This collaboration aimed to develop Promega’s microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) for use with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). In addition, this collaboration would initially seek regulatory approval for the Promega MSI CDx in the United States and China.

Apr-2019: PerkinElmer took over Cisbio Bioassays, a provider of a wide array of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies. This acquisition would allow life science researchers to have access to assay tools that resolve the wide diversity of target types and biological configurations, for both small molecule and biological drug discovery.

Scope of the Study

Market Segments covered in the Report:

By Method

• In-vitro

o Enzymatic

o Dye-based

o Co-translational

o Site-specific

o Nanoparticle

o Others

• In-vivo

o Photoreactive

o Radioactive

o Others

By Product

• Reagents

• Kits

• Services

By Application

• Immunological Techniques

• Cell-based Assays

• Fluorescence Microscopy

• Protein Microarray

• Mass Spectrometry

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Thermo Fisher Scientific, Inc.

• Merck Group

• PerkinElmer, Inc.

• General Electric (GE) Co.

• F. Hoffmann-La Roche Ltd.

• Kaneka Corporation

• New England BioLabs Inc.

• Promega Corporation

• LI-COR, Inc.

• SeraCare Life Sciences

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free